124 related articles for article (PubMed ID: 24614709)
1. A dimorphic blast population demonstrates Philadelphia-positive mixed phenotype acute leukaemia.
Ling VY; Wall M; Davis A; Gorniak M; Grigoriadis G
Pathology; 2014 Apr; 46(3):244-6. PubMed ID: 24614709
[No Abstract] [Full Text] [Related]
2. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.
Shimizu H; Yokohama A; Hatsumi N; Takada S; Handa H; Sakura T; Nojima Y
Eur J Haematol; 2014 Oct; 93(4):297-301. PubMed ID: 24750307
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
4. Chronic myelogenous leukemia for primary care physicians.
Torgerson SR; Haddad RY; Atallah E
Dis Mon; 2012 Apr; 58(4):168-76. PubMed ID: 22449366
[No Abstract] [Full Text] [Related]
5. Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia.
Chung Y; Eom HS; Lee H; Park S; Shim H; Cho EH; Kong SY
Ann Lab Med; 2014 Sep; 34(5):399-401. PubMed ID: 25187896
[No Abstract] [Full Text] [Related]
6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
Xu XH; Huang LS; Yang J; Yu T; Tong JF; Yuan XG; Zhao XY
Leuk Lymphoma; 2013 Jan; 54(1):195-7. PubMed ID: 22574970
[No Abstract] [Full Text] [Related]
8. Chronic myelogenous leukemia. Preface.
DeAngelo DJ
Hematol Oncol Clin North Am; 2011 Oct; 25(5):ix-x. PubMed ID: 22054737
[No Abstract] [Full Text] [Related]
9. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.
Bruennert D; Czibere A; Bruns I; Kronenwett R; Gattermann N; Haas R; Neumann F
Leukemia; 2009 May; 23(5):983-5. PubMed ID: 19052557
[No Abstract] [Full Text] [Related]
10. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Hwang YY; Tse E; So JC; Wan TS; Kwong YL
Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
[No Abstract] [Full Text] [Related]
11. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
12. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Imataki O
Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
[No Abstract] [Full Text] [Related]
13. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
[No Abstract] [Full Text] [Related]
14. [Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia].
Nagasawa F; Nakamura Y; Tokita K; Takahashi W; Iso H; Arai H; Tsurumi S; Handa T; Nakamura Y; Nakamura Y; Sasaki K; Mitani K
Rinsho Ketsueki; 2013 Nov; 54(11):2074-8. PubMed ID: 24305542
[TBL] [Abstract][Full Text] [Related]
15. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
[TBL] [Abstract][Full Text] [Related]
16. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
17. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
18. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
Jiménez-Velasco A; Barrios M; Alcalá M; Heiniger AI
J Clin Oncol; 2010 Jun; 28(18):e310; author reply e311. PubMed ID: 20479423
[No Abstract] [Full Text] [Related]
20. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.
Cherrier-De Wilde S; Rack K; Vannuffel P; Delannoy A; Hagemeijer A
Leukemia; 2003 Oct; 17(10):2046-8. PubMed ID: 14513056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
